Navigation Links
Avastin Rejection Supported by Cancer Experts

By Steven Reinberg
HealthDay Reporter

FRIDAY, July 1 (HealthDay News) -- Oncologists and even some breast cancer support groups are endorsing a U.S. health advisory panel's recommendation that the blockbuster cancer drug Avastin be removed for use in metastatic breast cancer.

The reason: There's still a lack of understanding of how the drug works or who it helps.

Avastin was given fast-track approval by the U.S. Food and Drug Administration in 2008 to be used, in combination with the chemotherapy drug Taxol, by women with metastatic HER2-negative breast cancer.

But a six-member FDA panel of cancer experts said Wednesday that the drug was not effective, caused dangerous side effects and its approval should be revoked.

The decision, which is non-binding, came at the end of a two-day hearing granted to Avastin maker Genentech after the FDA recommended last December revoking the drug's approval for metastatic breast cancer. The FDA cited the medication's poor performance in follow-up studies and its potential for serious side effects.

Karuna Jaggar, executive director of Breast Cancer Action, told HealthDay that "the panel made the right decision. We have been advocating for the FDA to take a critical stand on Avastin and really focus on overall survival," which hasn't been proven by any of the drug's studies so far.

Dr. Paula Klein, an oncologist specializing in breast cancer at Beth Israel Medical Center in New York City, said there may well be a subset of women for whom Avastin will extend life. But she faulted the drug maker for not trying to identify that group. "What Genentech has failed to do is spend the money necessary to find the subset of breast cancer patients that will benefit," she said.

Jaggar said she wished the evidence supporting Avastin had been stronger. She said she would support having Genentech doing a trial to try to identify women who would benefit from the drug. To date, any benefit from the drug has been based on anecdotal reports.

"But in the meantime, we do not believe Avastin should retain its approval on the hope we will eventually learn there are some women who do benefit from this treatment," Jaggar said. "We can't keep drugs on the market while we wait to see if they are effective."

Dr. Marc E. Lippman, deputy director of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, said he, too, supported the panel's decision. "I think they did a wise thing," he said.

But Lippman added that women should not stop taking Avastin based on the panel's recommendation. "I wouldn't, in my right mind, recommend discontinuing the drug from someone who is currently benefiting. It would be insane to stop the drug," he said.

And Klein said: "To women who are currently on the drug with advanced disease [and] doing well, you'd have to comfort them that there is a very good possibility that they will continue to do just as well with chemotherapy alone, if Avastin is no longer available. There is certainly a possibility of that."

In each trial of Avastin reviewed by the advisory panel, women who took the drug were also receiving chemotherapy, so it wasn't clear whether it was Avastin or the chemotherapy that was preventing their cancer from progressing. The trials also showed no benefit from the drug in extending life, despite the risk of serious side effects, including death.

"The gold standard has always been overall survival," Klein said. "This is one of the few drugs that was granted accelerated approval based on progression-free survival."

The hope was that studies would show the drug could extend overall survival, not just progression-free survival, Klein added, "but they failed to do it."

The advisory panel's decision now goes to FDA Commissioner Margaret Hamburg, who won't address the issue until the period for public comment ends July 28. Even if she revokes Avastin's use as a breast cancer drug, however, it will not be taken off the market because it is also used for advanced colon, lung, kidney and brain cancer.

And oncologists will still have the option of prescribing Avastin "off label" to their patients with metastatic breast cancer.

But Lippman noted that any FDA revocation of the drug's approval might prompt insurance companies to stop paying for Avastin, which can cost $80,000 a year. "I hope there would be some recommendation around that," he said.

Meanwhile, on Thursday, Don McLeod, a spokesman for the Centers for Medicare & Medicaid Services, said Medicare will continue to pay for the drug as a breast cancer treatment even if the FDA withdraws that approval.

However, Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, said even the panel's recommendation may make some doctors less willing to prescribe Avastin.

"The hope is that patients getting the drug who are having a good response will still have access to the drug. And, that's what's being put in jeopardy," she said.

In the midst of all the action and reaction in the United States, pharmaceutical giant Roche, which owns Genentech, announced on Thursday that the European Commission had just broadened Avastin's existing use in metastatic breast cancer, allowing it in tandem with the chemotherapy drug Xeloda.

More information

For more on breast cancer, visit the U.S. National Cancer Institute.

SOURCES: Marc E. Lippman, M.D., professor and chairman, department of medicine, deputy director, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine; Paula Klein, M.D., department of medicine, Beth Israel Medical Center, New York City; Stephanie Bernik, M.D., chief of surgical oncology, Lenox Hill Hospital, New York City; Marcia Donziger, CEO, Cancer Foundation, Denver; Don McLeod, spokesman, Centers for Medicare & Medicaid Services, Washington, D.C.; Karuna Jaggar, executive director, Breast Cancer Action

Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Panel Rejects Avastin for Breast Cancer
2. Cancer Drug Avastin Makes Inroads Against Ovarian Tumors
3. NIH study finds Avastin and Lucentis are equally effective in treating AMD
4. More Evidence Cancer Drug Avastin May Cause Harm
5. More Evidence Links Avastin to Heart Failure in Breast Cancer Patients
6. FDA Advises Against Avastin as Treatment for Breast Cancer
7. FDA Advisers Say Avastin Shouldnt Be Used for Breast Cancer
8. Avastin Largely Safe for Patients With Type of Advanced Lung Cancer
9. Romantic Rejection May Hurt Just Like Physical Pain
10. Gift-Giving, for Many Men, Means Avoiding Rejection
11. UCLA team uncovers mechanism behind organ transplant rejection
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has released a ... Mesothelioma has just posted the findings on the website. Click here to read ... of 136 mesothelioma patients who were treated with chemotherapy followed by EPP surgery. Among ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, ... The digital component is distributed nationally, through a vast social media strategy and ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced ... User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics ... software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College ... Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD ... colleges, as only one of twelve colleges and universities in the state of California ...
(Date:11/27/2015)... ... 27, 2015 , ... Indosoft Inc., developer and distributor of ... 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making ... with a version of Asterisk that will receive not only security fixes, but ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... has found that immunotherapy can be efficiently ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Advanced Wound Care Market by Type ... Ulcers), End User (In-Patient Facility, Out-Patient Facility), and Geography ... offering. --> --> ... the description, definition and forecast of the global advanced ...
Breaking Medicine Technology: